← Back to Screener
Century Therapeutics, Inc. Common Stock (IPSC)
Price$2.13
Value ScoreB
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)282.69%
Price vs S&P 500 (4W)-6.98%
VGM Score76.04
Market Capitalization$384.16M
All Metrics
Book Value / Share (Quarterly)$1.47
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)175.86%
Cash Flow / Share (Quarterly)$-0.53
Price vs S&P 500 (YTD)105.96%
Net Profit Margin (TTM)-18.92%
EPS (TTM)$-1.11
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$-1.11
EPS (Annual)$-0.11
ROI (Annual)-6.03%
Cash / Share (Quarterly)$0.75
ROA (Last FY)-4.28%
Revenue Growth TTM (YoY)1556.51%
EBITD / Share (TTM)$-0.90
ROE (5Y Avg)-45.18%
Operating Margin (TTM)-28.63%
Cash Flow / Share (Annual)$-1.20
P/B Ratio1.45x
P/B Ratio (Quarterly)1.53x
Net Income / Employee (Annual)$-122,800
EV / Revenue (TTM)2.90x
Net Interest Coverage (TTM)-90.50x
ROA (TTM)-39.93%
EPS Incl Extra (Annual)$-0.11
Current Ratio (Annual)5.97x
Quick Ratio (Quarterly)9.96x
3-Month Avg Trading Volume1.15M
52-Week Price Return278.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.28
P/S Ratio (Annual)3.52x
Asset Turnover (Annual)0.49x
52-Week High$3.04
EPS Excl Extra (Annual)$-0.11
CapEx CAGR (5Y)-43.36%
26-Week Price Return290.61%
Quick Ratio (Annual)5.83x
13-Week Price Return-16.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.25x
Enterprise Value$333.11M
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$1,399,500
Pretax Margin (Annual)-8.84%
Cash / Share (Annual)$1.34
3-Month Return Std Dev77.91%
Net Income / Employee (TTM)$-1,381,800
ROE (Last FY)-6.03%
Net Interest Coverage (Annual)-93.52x
EPS Basic Excl Extra (Annual)$-0.11
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.11
ROI (TTM)-53.23%
P/S Ratio (TTM)3.34x
Revenue / Share (Annual)$1.26
Tangible BV / Share (Annual)$1.43
Price vs S&P 500 (52W)253.96%
Year-to-Date Return114.11%
5-Day Price Return-9.75%
EPS Normalized (Annual)$-0.11
ROA (5Y Avg)-25.36%
Net Profit Margin (Annual)-8.78%
Month-to-Date Return-13.06%
Cash Flow / Share (TTM)$-1.98
EBITD / Share (Annual)$-0.05
Operating Margin (Annual)-15.82%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-44.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.11
P/TBV (Quarterly)1.76x
P/B Ratio (Annual)0.55x
Pretax Margin (TTM)-17.38%
Book Value / Share (Annual)$1.82
Price vs S&P 500 (13W)-25.05%
Beta1.57x
Revenue / Share (TTM)$0.00
ROE (TTM)-53.23%
52-Week Low$0.43
vGradeB
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.11est. -0.16
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IPSCCentury Therapeutics, Inc. Common Stock | B | A | B | $2.13 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Century Therapeutics develops allogeneic cell therapies for cancer, autoimmune, and inflammatory diseases using CRISPR-engineered stem cells and proprietary immune-evasion technology. The company's platform overcomes key limitations of first-generation cell therapies by reducing immune rejection and simplifying manufacturing. This approach enables faster development cycles, improved scalability, and reduced supply chain risks.